國家衛生研究院 NHRI:Item 3990099045/8832
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 857597      線上人數 : 664
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/8832


    題名: Copper-chelator exerts synergistic interaction with platinum drugs through modulating copper transporters in oxaliplatin-resistant human gastric cancer cell
    作者: Chen, SJ;Chang, JY;Kuo, CC;Pan, HY
    貢獻者: National Institute of Cancer Research;Institute of Biotechnology and Pharmaceutical Research
    摘要: Although platinum-based chemotherapy drugs including cisplatin, carboplatin, and oxaliplatin are commonly used in the treatment of human solid tumor, patients ultimately develop drug-resistance and result in treatment failure. Combination copper-chelator with platinum drugs has been reported to successfully treat a subset of cisplatin- resistant ovarian cancer patients. However, the underlying mechanisms of action remain unknown. We have previously established an oxaliplatin-resistant subclone from human gastric adenocarcinoma TSGH cells, S3. The mechanisms responsible for oxaliplatin resistance of S3 cells included down-regulation of hCtr1 and over-expression of ATP7A. In contrast to displaying additive to antagonistic interaction with platinum drugs in parental, TSGH cells, our studies showed that copper-chelator, D-penicillamine, exerts synergistic interaction with platinum drugs through increasing platinum- DNA adduct formations in S3 cells. D-penicillamine promotes copper uptake transporter hCtr1 expression via activation of transcription factor Sp1. In addition, Sp1 overexpression promotes p53 translocation from nucleus to cytosol and binds to ubiquitin, and finally causes p53 degradation, which further suppressed the expression of copper efflux transporter, ATP7A. Combination of D-penicillamine and oxaliplatin significantly inhibited S3 cell growth in animal model. Immunohistochemical analysis showed that up-regulation of hCtr1 and down-regulation of ATP7A were found in both D-penicillamine- and D-penicillamine/ Oxalipatin- treated S3 tumors, which were consistence to in vitro results. In conclusion, our results showed that D-penicillamine increases hCtr1 expression through regulating Sp1 level. Notably, D-penicillamine could down-regulate ATP7A expression through regulation of p53. Our finding demonstrated a new treatment strategy for cancer patient resistant to oxaliplatin treatment with low expression of hCtr1 and overexpression of ATP7A in tumor tissues.
    日期: 2014-10
    關聯: Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 3753.
    Link to: http://dx.doi.org/10.1158/1538-7445.am2014-3753
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0008-5472&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000349910201243
    顯示於類別:[張俊彥] 會議論文/會議摘要
    [郭靜娟] 會議論文/會議摘要

    文件中的檔案:

    沒有與此文件相關的檔案.



    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋